WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 16, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
Next Generation FRα-Targeting ADC Engineered to Maximize Potential Clinical Benefit for Patients with Lower FRα Expression Potent Anti-Tumor Activity Exhibited in Ovarian Cancer and Other Tumor Types Regardless of FRα Expression Level WALTHAM, Mass. --(BUSINESS WIRE)--Jun.
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 3, 2020-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the 2020 Annual Meeting of Shareholders (the “Annual Meeting”) will be held virtually due to the
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 2, 2020-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on May 29, 2020 the compensation committee of the Company’s Board of Directors granted non-qualified
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 1, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Stacy A. Coen has been appointed Senior Vice President and Chief Business Officer.
With a Confirmed Overall Response Rate of 64% and Favorable Tolerability in Patients with High FRα Expression, Combination Demonstrates Encouraging Outcomes Relative to Available Regimens WALTHAM, Mass. --(BUSINESS WIRE)--May 29, 2020-- ImmunoGen, Inc.
WALTHAM, Mass. --(BUSINESS WIRE)--May 20, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy , President and CEO, and Anna Berkenblit , Chief Medical Officer, will participate in a
Next Generation Anti-FRα ADC Demonstrates Potent Anti-Tumor Activity in Ovarian Cancer Models and Other FRα-positive Tumor Types in Preclinical Studies WALTHAM, Mass. --(BUSINESS WIRE)--May 15, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs)
Combination Demonstrates Promising Anti-Tumor Activity and Favorable Tolerability, with a Confirmed Overall Response Rate of >60% in Patients with High FRα Expression Results to be Presented in an Oral Session at ASCO 2020 Virtual Scientific Program WALTHAM, Mass.
WALTHAM, Mass. --(BUSINESS WIRE)--May 6, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy , President and CEO, and Anna Berkenblit , Chief Medical Officer, will participate in a